Artiva Biotherapeutics nets $120m Series B

Artiva Biotherapeutics, Inc., an oncology-focused biopharmaceutical company, has secured $120 million in Series B financing.

Artiva Biotherapeutics, Inc., an oncology-focused biopharmaceutical company, has secured $120 million in Series B financing. Venrock Healthcare Capital Partners led the round.

Source: Press Release